Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose weight more effectively and stay on track with its flagship medication, Wegovy ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses.

Despite Novo Nordisk's stock decline, the company's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases. Eli Lilly's oral weight-loss drug ...

Septerna is eligible to receive approximately 2.2 billion US dollars, including more than 200 million dollars in upfront and near-term payments South San Francisco, California, US and Bagsværd ...

Danish pharmaceutical giant Novo Nordisk and U.S. biotech Septerna agreed to collaborate on the development of pills to treat obesity, type 2 diabetes and other metabolic conditions. Under the ...

By Rebecca Robbins Novo Nordisk will replace its chief executive, Lars Fruergaard Jorgensen, the company announced Friday, citing a sharp decline in its stock price that stemmed from increased ...

Novo Nordisk, the maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by "mutual agreement" with the company's board of directors, citing "recent market challenges ...